Healthcare company Novo Nordisk reported on Monday the receipt of approval from the US Food and Drug Administration (FDA) for Fiasp (insulin aspart injection) 100 u/ml for use as a new mealtime insulin option for children with diabetes.
Fiasp, which is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation, is administered at the beginning of a meal or within 20 minutes after starting a meal. It is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation, added the company.
According to the company, Fias is now available for use in children and adults in three different dosing options: multiple daily injections (MDI), continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.
This US FDA approval of Fiasp for paediatric use was based on data from the company's onset 7, a 26-week, phase 3b, partially double-blind, basal-bolus, treat-to-target trial, which investigated the efficacy and safety of Fiasp compared with conventional insulin aspart in 777 children with type 1 diabetes, one of the most common chronic conditions diagnosed in childhood, with nearly 18,000 new cases each year.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT